Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
Following a presentation at the annual meeting of the American Academy of Ophthalmology a number of media reports have reported a possible link between use of combined oral contraception (COC) and glaucoma. There is limited data investigating combined hormonal contraceptives on glaucoma. One cohort study suggested that 5 or more years of COC use was associated with a 25% increase in the risk of glaucoma. Two UK cohort studies did not find consistent evidence of an increased risk.
FSRH CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)
Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.
Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).
The combined oral contraceptive Zoely® (Merck, Sharp, and Dohme Limited) has been licensed in Europe since 2011 and will be available in the UK from May 2013. Zoely will be the second UK combined oral contraceptive (COC) to contain estradiol and to be formulated as an extended regimen since the introduction of Qlaira® (Bayer plc.)
This document provides standards for resuscitation in sexual and reproductive health service settings. This document should be used in conjunction with national guidelines from other relevant professional bodies and locally agreed policies and procedures. It is important that each service identifies the level of equipment and training needed to deal with common emergencies on the basis of a local risk assessment.
These Standards are recommended for organisations providing contraceptive/sexual and reproductive health (SRH) services, including pregnancy planning, pregnancy choices, abortion, prevention and treatment of sexually transmitted infections (STIs), as well as sexual wellbeing and health promotion.
This statement provides guidance on contraceptive options for women with prolactinoma
FSRH Clinical Guideline: Management of Vaginal Discharge in Non-Genitourinary Medicine Settings (February 2012), Lapsed Guideline
Please note, this guidance document has lapsed. Up to date guidance on this topic can be found at: http://www.rcgp.org.uk/clinical-and-research/clinical-resources/sexually-transmitted-infections-in-primary-care.aspx